Abemaciclib in Treating Patients with Recurrent Brain Tumors
- COHORT A SPECIFIC INCLUSION: Histologically confirmed IDHwt, retinoblastoma (RB) intact, grade II or III glioma that has recurred after first line therapy (consisting of at least maximum feasible surgical resection and radiation therapy); there is no limit on the number of prior therapies or types of therapies patients can have received
- COHORT A SPECIFIC INCLUSION: Measurable disease on imaging (1 cm) or measurable non-enhancing tumor
- COHORT A SPECIFIC INCLUSION: At least 12 weeks elapsed since prior radiotherapy
- COHORT B SPECIFIC INCLUSION: Patients with histologically confirmed glioma of any grade (II-IV) who are planned for a standard of care surgical debulking/resection and for whom participation in this study would not cause a medically unacceptable delay in surgery
- COHORT B SPECIFIC INCLUSION: Patients must have relapsed/progressed following therapy (consisting of at least maximum feasible surgical resection and radiation therapy)
- COHORT C SPECIFIC INCLUSION: Histologically confirmed IDH mutant glioma, meningioma, schwanoma, PCNSL, ependymoma, or other primary brain tumors that have recurred despite previous standard of care therapy; because this cohort is, in part, meant to allow patients access to therapy who might not otherwise be eligible for other clinical trials - deviations from standard of care treatment or histological confirmation can be presented to and approved by the principal investigator for inclusion in the study
- COHORT C SPECIFIC INCLUSION: Histologically confirmed PCNSL that has recurred after prior methotrexate-based chemotherapy or for whom methotrexate-based chemotherapy is deemed medically not in the patient's best interest
- GLIOMA PATIENTS: Standard of care next generation sequencing via a Clinical Laboratory Improvement Act (CLIA) certified platform must be available, or planned, and at a minimum include IDH and RB status
- Patients must provide written informed consent prior to any screening procedures
- Karnofsky performance status (KPS) >= 60
- Willing and able to comply with scheduled visits, treatment plan and laboratory tests
- Patient is able to swallow and retain oral medication
- Hemoglobin > 8 g/dL (international system [SI] units: 80 g/L); patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator; initial treatment must not begin earlier than the day after the erythrocyte transfusion
- Platelet count >= 100 x 10^9/L
- Absolute neutrophil count (ANC) >= 1.5 x 10^9/L without growth factor support
- Total bilirubin =< 1.5 x upper limit of normal (ULN)
- Aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) and/or alanine aminotransferase (ALT)/serum glutamate pyruvate transaminase (SGPT) =< 3 x ULN
- Serum creatinine =< 1.5 x ULN
- Stable dose of corticosteroids for >= 5 days prior to baseline magnetic resonance imaging (MRI)
- Before starting study treatment, patients must have recovered from toxic effects of prior therapies (except for residual alopecia or grade 2 peripheral neuropathy) and at least 3 weeks must have elapsed since any prior signaling pathway modulators, (e.g., EGFR, FGFR, or other tyrosine kinase inhibitors), at least 3 weeks must have elapsed since temozolomide, 4 weeks must have elapsed since carboplatin or cisplatin, and at least 6 weeks from nitrosoureas (e.g., carmustine [BCNU], lomustine [CCNU]); in general, at least 4 weeks must have elapsed from any other anticancer drug therapy (e.g. bevacizumab)
- Patients must be able to undergo contrast enhanced MRI scans (or contrast enhanced computed tomography [CT] scans for patients unable to tolerate MRI)
- Patients must have shown unequivocal evidence for tumor progression by MRI (or CT for patients who cannot tolerate MRI) in comparison to a prior scan; the same type of scan, i.e., MRI (or CT for patients who cannot undergo MRI) must be used throughout the period of protocol treatment for tumor measurement
- Life expectancy of greater than 8 weeks
- If a female of childbearing potential, must have a negative serum pregnancy test within 7 days of the first dose of abemaciclib and agree to use a medically approved contraceptive method during the treatment period and for 3 months following the last dose of abemaciclib; if a male, agree to use a reliable method of birth control and to not donate sperm during the treatment period and for at least 3 months following the last dose of abemaciclib; contraceptive methods may include an intrauterine device (IUD) or barrier method; if condoms are used as a barrier method, a spermicidal agent should be added as a double barrier protection * Note: cases of pregnancy that occur during maternal exposures to abemaciclib should be reported; if a patient or spouse/partner is determined to be pregnant following abemaciclib initiation, she must discontinue treatment immediately; data on fetal outcome and breast-feeding are collected for regulatory reporting and drug safety evaluation
- Women must agree not to breast feed while on abemaciclib treatment and for at least three months following the last dose of study therapy
- No limit on number of prior therapies
- Evidence of significant intracranial hemorrhage
- No other investigational or standard anti-tumor therapy allowed
- Patients must not have a known history of allergic reactions attributed to compounds of similar chemical or biologic composition
- Patients must not have a serious preexisting medical condition(s) or uncontrolled intercurrent illness that would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline grade 2 or higher diarrhea) or psychiatric illness/social situations that would limit compliance with study requirements
- Patients who have a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological original (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest
- Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions. This applies only to patients who have a documented history of HIV; HIV testing is not otherwise required
- Have an active systemic fungal and/or known viral infection (for example, human immunodeficiency virus antibodies, hepatitis B surface antigen, or hepatitis C antibodies)
- Patients must not be on enzyme-inducing antiepileptic drugs (EIAEDs)
- Females who are pregnant or lactating
- Must abstain from grapefruit juice
- Patients must not have other active concurrent malignancy
- Concurrent treatment on another clinical trial; supportive care trials or non-therapeutic trials (i.e. quality of life) are allowed
I. To estimate the efficacy of abemaciclib in patients with recurrent IDH wild-type (wt) gliomas as measured by the clinical benefit rate (combined radiographic response or 6-month progression-free survival [PFS] rate) (cohort A).
I. Further explore the safety and toxicity of abemaciclib in patients with primary brain tumors (all cohorts).
II. Estimate median overall survival (OS), median PFS, radiographic response rate, and best radiographic response in patients with recurrent IDHwt astrocytoma treated with abemaciclib (cohort A).
I. To describe radiographic response rate, best radiographic response, and survival in patients with recurrent IDH mutant astrocytoma and oligodendroglioma, CDKN2A/B deficient or CDK4 amplified glioblastoma (GBM), meningioma, ependymoma, and primary central nervous system lymphoma (PCNSL) (cohort B and C).
II. Explore the association of pretreatment molecular phenotype (i.e. IDH mutant versus [vs.] wildtype) with response to treatment (cohorts A, B, and C).
III. Explore molecular effects during treatment including cell cycle regulatory markers (cohort B).
IV. Explore pharmacodynamic effects and tissue pharmacokinetics of abemaciclib in patients undergoing standard of care resection (cohort B).
OUTLINE: Patients are assigned to 1 of 2 groups.
GROUP I: Patients receive abemaciclib orally (PO) twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. (on-hold as of 06/09/2020)
GROUP II: Patients receive abemaciclib PO BID on days 1-4 or 1-7 prior to standard of care surgery. Beginning 2-6 weeks after surgery, patients receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. (closed to accrual as of 06/09/2020)
After completion of study treatment, patients are followed up at 28 days and then periodically thereafter.
Trial Phase Phase II
Trial Type Treatment
Memorial Sloan Kettering Cancer Center
Thomas J. Kaley
- Primary ID 17-261
- Secondary IDs NCI-2017-01349
- Clinicaltrials.gov ID NCT03220646